285 related articles for article (PubMed ID: 26652296)
1. Intracellular and extracellular microtubule associated protein tau as a therapeutic target in Alzheimer disease and other tauopathies.
Avila J; Pallas N; Bolós M; Sayas CL; Hernandez F
Expert Opin Ther Targets; 2016 Jun; 20(6):653-61. PubMed ID: 26652296
[TBL] [Abstract][Full Text] [Related]
2. Tau-based therapies in neurodegeneration: opportunities and challenges.
Li C; Götz J
Nat Rev Drug Discov; 2017 Dec; 16(12):863-883. PubMed ID: 28983098
[TBL] [Abstract][Full Text] [Related]
3. Novel drugs affecting tau behavior in the treatment of Alzheimer's disease and tauopathies.
Navarrete LP; Pérez P; Morales I; Maccioni RB
Curr Alzheimer Res; 2011 Sep; 8(6):678-85. PubMed ID: 21605038
[TBL] [Abstract][Full Text] [Related]
4. Recent developments with tau-based drug discovery.
Iqbal K; Liu F; Gong CX
Expert Opin Drug Discov; 2018 May; 13(5):399-410. PubMed ID: 29493301
[TBL] [Abstract][Full Text] [Related]
5. Tau pathology in Alzheimer disease and other tauopathies.
Iqbal K; Alonso Adel C; Chen S; Chohan MO; El-Akkad E; Gong CX; Khatoon S; Li B; Liu F; Rahman A; Tanimukai H; Grundke-Iqbal I
Biochim Biophys Acta; 2005 Jan; 1739(2-3):198-210. PubMed ID: 15615638
[TBL] [Abstract][Full Text] [Related]
6. Alzheimer's disease: phenotypic approaches using disease models and the targeting of tau protein.
Lauretti E; Praticò D
Expert Opin Ther Targets; 2020 Apr; 24(4):319-330. PubMed ID: 32116063
[No Abstract] [Full Text] [Related]
7. Dementia Therapy Targeting Tau.
Buee L
Adv Exp Med Biol; 2019; 1184():407-416. PubMed ID: 32096053
[TBL] [Abstract][Full Text] [Related]
8. Sources of extracellular tau and its signaling.
Avila J; Simón D; Díaz-Hernández M; Pintor J; Hernández F
J Alzheimers Dis; 2014; 40 Suppl 1():S7-S15. PubMed ID: 24531154
[TBL] [Abstract][Full Text] [Related]
9. What is the pathological significance of tau oligomers?
Cowan CM; Quraishe S; Mudher A
Biochem Soc Trans; 2012 Aug; 40(4):693-7. PubMed ID: 22817718
[TBL] [Abstract][Full Text] [Related]
10. Microtubule-associated protein tau as a therapeutic target in Alzheimer's disease.
Iqbal K; Gong CX; Liu F
Expert Opin Ther Targets; 2014 Mar; 18(3):307-18. PubMed ID: 24387228
[TBL] [Abstract][Full Text] [Related]
11. Further understanding of tau phosphorylation: implications for therapy.
Medina M; Avila J
Expert Rev Neurother; 2015 Jan; 15(1):115-22. PubMed ID: 25555397
[TBL] [Abstract][Full Text] [Related]
12. Phosphorylated tau targeted small-molecule PROTACs for the treatment of Alzheimer's disease and tauopathies.
Jangampalli Adi P; Reddy PH
Biochim Biophys Acta Mol Basis Dis; 2021 Aug; 1867(8):166162. PubMed ID: 33940164
[TBL] [Abstract][Full Text] [Related]
13. Phosphorylated mitogen-activated protein kinase (MAPK/ERK-P), protein kinase of 38 kDa (p38-P), stress-activated protein kinase (SAPK/JNK-P), and calcium/calmodulin-dependent kinase II (CaM kinase II) are differentially expressed in tau deposits in neurons and glial cells in tauopathies.
Ferrer I; Blanco R; Carmona M; Puig B
J Neural Transm (Vienna); 2001; 108(12):1397-415. PubMed ID: 11810404
[TBL] [Abstract][Full Text] [Related]
14. Increase in tau tyrosine phosphorylation correlates with the formation of tau aggregates.
Vega IE; Cui L; Propst JA; Hutton ML; Lee G; Yen SH
Brain Res Mol Brain Res; 2005 Aug; 138(2):135-44. PubMed ID: 15913839
[TBL] [Abstract][Full Text] [Related]
15. Targeting the ensemble of heterogeneous tau oligomers in cells: A novel small molecule screening platform for tauopathies.
Lo CH; Lim CK; Ding Z; Wickramasinghe SP; Braun AR; Ashe KH; Rhoades E; Thomas DD; Sachs JN
Alzheimers Dement; 2019 Nov; 15(11):1489-1502. PubMed ID: 31653529
[TBL] [Abstract][Full Text] [Related]
16. Tau phosphorylation and aggregation in Alzheimer's disease pathology.
Avila J
FEBS Lett; 2006 May; 580(12):2922-7. PubMed ID: 16529745
[TBL] [Abstract][Full Text] [Related]
17. Twice is better: highlights of the second meeting focused on tau biology and pathology.
Skoulakis EM; Mudher A
Biochem Soc Trans; 2012 Aug; 40(4):641-3. PubMed ID: 22817708
[TBL] [Abstract][Full Text] [Related]
18. O-GlcNAcase inhibitors as potential therapeutics for the treatment of Alzheimer's disease and related tauopathies: analysis of the patent literature.
Bartolomé-Nebreda JM; Trabanco AA; Velter AI; Buijnsters P
Expert Opin Ther Pat; 2021 Dec; 31(12):1117-1154. PubMed ID: 34176417
[No Abstract] [Full Text] [Related]
19. Tauopathies and tau oligomers.
Takashima A
J Alzheimers Dis; 2013; 37(3):565-8. PubMed ID: 23948895
[TBL] [Abstract][Full Text] [Related]
20. Expression of a truncated tau protein induces oxidative stress in a rodent model of tauopathy.
Cente M; Filipcik P; Pevalova M; Novak M
Eur J Neurosci; 2006 Aug; 24(4):1085-90. PubMed ID: 16930434
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]